LOTUSEYE - Lotus Eye Hospit
📢 Recent Corporate Announcements
Lotus Eye Hospital and Institute Limited has addressed the imposition of fines by BSE and NSE regarding non-compliance with SEBI (LODR) Regulation 17(1A). The dispute arose from a difference in interpretation regarding whether a change in a director's designation constitutes a new appointment requiring specific approvals for directors over 75 years of age. While the company maintained a different view, it has since paid the fine and committed to full compliance with law in letter and spirit. The board reviewed these developments on February 11, 2026, to reinforce corporate governance standards.
- BSE and NSE imposed fines for non-compliance with SEBI (LODR) Regulation 17(1A) concerning director appointments.
- The company disputed the exchanges' view that a change in designation is equivalent to a new appointment.
- Lotus Eye Hospital has officially paid the fine to both stock exchanges to resolve the regulatory issue.
- The Board of Directors reaffirmed its commitment to corporate governance in a meeting held on February 11, 2026.
Lotus Eye Hospital and Institute Limited has appointed Mr. Prathish S as its new Company Secretary and Compliance Officer, effective February 13, 2026. The appointment was approved by the Board of Directors on February 11, 2026, following recommendations from the Nomination and Remuneration Committee. Mr. Prathish S is an Associate Member of the ICSI (A73669) and an alumnus of the prestigious Shri Ram College of Commerce. This transition fills a Key Managerial Personnel (KMP) role responsible for corporate governance and regulatory reporting.
- Appointment of Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
- The appointee is an Associate Member of ICSI with Membership No. A73669.
- Educational background includes a degree from Shri Ram College of Commerce (SRCC), University of Delhi.
- The Board of Directors approved the appointment in a meeting held on February 11, 2026.
Lotus Eye Hospital and Institute Limited reported a net loss of ₹26.07 lakhs for the quarter ended December 31, 2025, a decline from a profit of ₹11.58 lakhs in the preceding quarter. While revenue from operations grew 10.6% year-on-year to ₹1,354.96 lakhs, total expenses rose significantly to ₹1,416.07 lakhs, leading to the loss. For the nine-month period ended December 2025, the company's net profit stands at ₹39.99 lakhs, down from ₹48.69 lakhs in the previous year. The board also appointed Mr. Prathish S as the new Company Secretary and Compliance Officer.
- Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs in Q3 FY26.
- Reported a net loss of ₹26.07 lakhs for the quarter compared to a profit of ₹11.58 lakhs in Q2 FY26.
- Total expenses rose to ₹1,416.07 lakhs, driven by higher service expenses of ₹276.74 lakhs and employee benefits of ₹313.76 lakhs.
- Nine-month net profit declined to ₹39.99 lakhs from ₹48.69 lakhs in the previous year's corresponding period.
- Appointment of Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
Lotus Eye Hospital and Institute Limited reported a 10.6% year-on-year growth in revenue from operations to ₹1,354.96 lakhs for the quarter ended December 31, 2025. Despite the revenue growth, the company reported a net loss of ₹26.07 lakhs for the quarter, compared to a profit of ₹11.58 lakhs in the preceding quarter. Total expenses rose to ₹1,416.07 lakhs, driven by increased service and employee benefit costs. For the nine-month period ended December 2025, net profit declined by 17.9% to ₹39.99 lakhs compared to the previous year.
- Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs from ₹1,224.69 lakhs.
- Reported a net loss of ₹26.07 lakhs in Q3 FY26 versus a profit of ₹11.58 lakhs in Q2 FY26.
- Total expenses for the quarter rose to ₹1,416.07 lakhs, exceeding total income of ₹1,378.51 lakhs.
- Nine-month net profit decreased to ₹39.99 lakhs from ₹48.69 lakhs in the corresponding period last year.
- Appointed Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
Lotus Eye Hospital and Institute Limited has announced the resignation of Mr. M Achuth Menon from the post of Company Secretary and Compliance Officer. The resignation is set to be effective from the close of business hours on February 12, 2026. This transition requires the company to appoint a new officer to handle regulatory and secretarial duties. Such changes are generally routine but essential for maintaining corporate governance standards.
- Resignation of M Achuth Menon as Company Secretary and Compliance Officer.
- The effective date of resignation is fixed for February 12, 2026.
- The official notification was released on February 9, 2026.
- Company must now initiate the process to appoint a successor for regulatory compliance.
Lotus Eye Hospital and Institute Limited has successfully passed three special resolutions via postal ballot with overwhelming shareholder support. The resolutions include the continuation and appointment of Dr. K.S. Ramalingam as a Non-Executive Director and the reappointment of Dr. S. Natesan as an Independent Director for a second five-year term. All resolutions received 99.0661% votes in favor, representing 78,50,995 shares. The voting process concluded on January 17, 2026, ensuring leadership continuity for the hospital chain.
- Resolution to continue Dr. K.S. Ramalingam as Non-Executive Director passed with 99.07% assent.
- Dr. S. Natesan reappointed as Independent Director for a second consecutive term of 5 years.
- Total valid votes cast for each resolution amounted to 79,25,006 shares.
- Dissenting votes were minimal, accounting for only 0.9339% of the total votes cast.
- All resolutions are deemed passed effective from January 17, 2026.
Lotus Eye Hospital and Institute Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ending December 31, 2025. The filing confirms that all share certificates received for dematerialization were processed, mutilated, and cancelled according to regulatory standards. This process was completed within the required 15-day timeframe by the company's Registrar, MUFG Intime India Private Limited. Such filings are standard procedure to maintain accurate electronic shareholding records and ensure regulatory compliance.
- Quarterly compliance certificate submitted for the period ended December 31, 2025.
- Dematerialization requests were processed and records updated within the 15-day statutory limit.
- MUFG Intime India Private Limited (formerly Link Intime) acted as the Registrar and Transfer Agent.
- Confirmed that dematerialized securities are listed on the Stock Exchanges where earlier shares are listed.
Lotus Eye Hospital and Institute Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is in anticipation of the upcoming financial results for the quarter ended December 31, 2025. The window will remain closed for all designated persons and directors until 48 hours after the results are declared. The specific date for the board meeting to approve these results will be communicated at a later date.
- Trading window closure effective from January 1, 2026
- Closure pertains to the financial results for the quarter ended December 31, 2025
- Window to reopen 48 hours after the official announcement of results
- Applicable to all directors and designated persons as per SEBI norms
Lotus Eye Hospital and Institute Limited has issued a correction regarding its previous announcement dated December 18, 2025, concerning a Postal Ballot Notice. The company identified an inadvertent error where the voting end date was incorrectly stated as December 17, 2026. The corrected voting period is now officially set from December 19, 2025, to January 17, 2026. This update is purely procedural to ensure accurate regulatory compliance and shareholder voting timelines.
- Correction of a clerical error in the Postal Ballot Notice originally filed on December 18, 2025
- Revised voting end date is January 17, 2026, instead of the previously stated December 17, 2026
- The official voting window is confirmed as December 19, 2025, to January 17, 2026
- All other terms and contents of the original Postal Ballot announcement remain unchanged
Lotus Eye Hospital and Institute Limited has initiated a postal ballot to seek shareholder approval for three key board-level resolutions. The company is proposing the continuation and subsequent formal appointment of Dr. KS Ramalingam as a Non-Executive Director effective from June 2025 and February 2026, respectively. Additionally, the board seeks to re-appoint Dr. S Natesan as an Independent Director for a second five-year term spanning 2026 to 2031. Shareholders can cast their votes electronically between December 19, 2025, and January 17, 2026.
- Proposed continuation of Dr. KS Ramalingam as Non-Executive Director from June 1, 2025, to February 8, 2026.
- Formal appointment of Dr. KS Ramalingam as Non-Executive Director effective February 9, 2026, liable to retirement by rotation.
- Re-appointment of Dr. S Natesan as an Independent Director for a second 5-year term from January 3, 2026, to January 3, 2031.
- Remote e-voting period is scheduled from December 19, 2025, to January 17, 2026, with a cut-off date of December 16, 2025.
Lotus Eye Hospital and Institute Limited has approved the re-appointment of Dr. S Natesan as an Independent Director for a second consecutive term of five years. The new term is effective from January 3, 2026, and will run until January 3, 2031, subject to shareholder approval via a special resolution. Dr. Natesan is a veteran in the medical field with over 50 years of experience in medicine and hospital administration. This appointment aims to maintain board continuity and leverage his extensive healthcare expertise.
- Dr. S Natesan re-appointed for a second 5-year term effective from January 3, 2026, to January 3, 2031
- The appointee brings over 50 years of experience in the medical field and hospital administration
- Appointment was approved by the Board on December 15, 2025, via circular resolution
- The re-appointment is subject to the passing of a Special Resolution by the company's shareholders
Financial Performance
Revenue Growth by Segment
Revenue from operations for FY21 was INR 32.37 Cr, representing a 20.18% decline from INR 40.55 Cr in FY20, primarily due to pandemic-related disruptions. However, Q4 FY21 showed a strong recovery with revenue of INR 10.57 Cr, growing 29.36% YoY from INR 8.17 Cr. The business is primarily a single-segment healthcare provider focusing on ophthalmology.
Geographic Revenue Split
The company operates across Tamil Nadu and Kerala. Key locations include Coimbatore (RS Puram, Peelamedu, Saravanampatti), Salem, Tirupur, Mettupalayam, and Karur in Tamil Nadu, and Kochi (Kadavanthara, Mulanthuruty) in Kerala. While specific % splits per city are not disclosed, Tamil Nadu remains the primary revenue contributor.
Profitability Margins
For FY21, the company reported a Profit Before Tax of INR 1.91 Cr on a Total Income of INR 33.11 Cr, yielding a margin of 5.77%. In Q2 FY26 (quarter ended Sept 30, 2025), the Net Profit was INR 11.58 lakhs on a Total Income of INR 13.04 Cr, showing a significant margin compression to approximately 0.89% compared to previous periods.
EBITDA Margin
Operating profitability for FY21 (calculated as Total Income minus operating expenses excluding depreciation and finance costs) was approximately INR 4.65 Cr, representing an EBITDA margin of 14.04%. This was a decrease from the previous year's higher base due to fixed employee costs (INR 6.97 Cr) and other expenses (INR 14.38 Cr) despite lower revenue.
Capital Expenditure
For the half-year ended September 30, 2025, the company invested INR 1.66 Cr in the purchase of property, plant, and equipment. This reflects ongoing upgrades to medical technology and facility maintenance.
Credit Rating & Borrowing
Not disclosed in available documents; however, finance costs for the period ended September 30, 2025, were reported at INR 22.68 lakhs, indicating manageable debt levels or lease liabilities.
Operational Drivers
Raw Materials
Medical consumables (lenses, surgical kits, medicines) and stock-in-trade (optical frames and spectacles). Cost of materials consumed represented 15.7% of revenue (INR 5.09 Cr) in FY21, while purchase of stock-in-trade accounted for 14.7% (INR 4.76 Cr).
Import Sources
Not specifically disclosed, but medical equipment and high-end intraocular lenses are typically sourced from global medical technology hubs or domestic distributors in India.
Capacity Expansion
The company operates multiple centers across 7+ locations. Recent expansions include the addition of new board members and a focus on 'Green Business' practices at the Salem branch, which was ranked 1st runner-up in the Rotary Club Salem Green Business Awards 2020.
Raw Material Costs
Total material and stock costs for FY21 were INR 9.85 Cr, roughly 30.4% of revenue. Procurement strategies involve a mix of direct consumption for surgeries and retail stock for optical outlets.
Manufacturing Efficiency
In Q4 FY21, the company screened 2,800+ eyes and registered 5,000+ new patients, indicating high throughput and utilization of clinical staff post-COVID.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
The company is focusing on enhancing recurring revenue through its optical retail and pharmacy wings. It is also aggressively pursuing digital marketing (1.76 Cr ad impressions) and national television promotions (Star Vijay) to increase brand visibility. Expansion is driven by corporate and public eye camps (2,800+ screened in Q4 FY21) to build a patient pipeline.
Products & Services
Ophthalmology services including Cataract surgery, LASIK, Glaucoma treatment, and Optometry. Retail sales of spectacles, frames, and contact lenses.
Brand Portfolio
LOTUS, Lotus Eye Hospital and Institute.
New Products/Services
Establishment of efficient and accessible optometry institutions and counseling centers for the underprivileged to expand the service ecosystem.
Market Expansion
Targeting deeper penetration in the Tamil Nadu and Kerala markets through satellite centers and community outreach programs.
Market Share & Ranking
Not disclosed in available documents, but recognized as a leading eye care provider in the Coimbatore and Salem regions.
Strategic Alliances
Partnerships with organizations like the Rotary Club for community health initiatives and 'Green Business' certifications.
External Factors
Industry Trends
The eye care industry is shifting toward technology-heavy diagnostics and minimally invasive surgeries. Lotus is positioning itself by investing in digital branding and modernizing its equipment (INR 1.66 Cr Capex in H1 FY26).
Competitive Landscape
Competes with regional eye care chains and multi-specialty hospitals in South India.
Competitive Moat
The company's moat is built on its 25+ year brand legacy in South India, a network of specialized hospitals, and a new management team led by MD Ms. Sangeetha Sundaramoorthy. This regional reputation acts as a barrier to entry for new competitors.
Macro Economic Sensitivity
Highly sensitive to healthcare spending and elective surgery demand. GDP growth and rising middle-class disposable income drive demand for premium eye care services like LASIK.
Consumer Behavior
Increasing awareness of eye health and rising prevalence of digital eye strain are driving higher patient volumes for optometry and corrective procedures.
Geopolitical Risks
Limited, as operations are domestic, but global supply chains for medical equipment could be affected by trade barriers.
Regulatory & Governance
Industry Regulations
Subject to the Companies Act 2013, SEBI LODR 2015, and healthcare-specific standards. Non-compliance with Regulation 17(1A) led to monetary penalties in 2025.
Environmental Compliance
The Salem unit received a 'Green Business' award, indicating a focus on sustainable operations, though specific ESG costs are not quantified.
Taxation Policy Impact
The company faces uncertain tax positions related to direct and indirect taxes, which are subject to periodic challenges by authorities. Current tax for Q2 FY26 was INR 27.09 lakhs.
Legal Contingencies
The company has disclosed pending litigations in Note 44 of its financial statements. While the specific INR value is not provided in the summary, these include tax matters and other legal challenges that could impact the financial position.
Risk Analysis
Key Uncertainties
Regulatory risks regarding board composition and SEBI compliance (potential for further fines). Operational risks include the ability to attract and retain specialized surgeons.
Geographic Concentration Risk
100% of revenue is concentrated in Tamil Nadu and Kerala, making the company vulnerable to regional economic or regulatory changes in these two states.
Third Party Dependencies
Dependency on medical equipment manufacturers for maintenance and supply of specialized surgical consumables.
Technology Obsolescence Risk
High risk in the ophthalmology sector; failure to upgrade to the latest LASIK or diagnostic technology could result in loss of market share to more modern facilities.
Credit & Counterparty Risk
Trade receivables stood at INR 2.15 Cr as of September 30, 2025, indicating a relatively low credit risk given the cash-and-carry nature of most healthcare services.